ENTA vs AGIO vs FOLD vs PRTA

For growth investors, Agios Pharmaceuticals, Inc.

(AGIO) is the stronger pick with 48. 0% revenue growth year-over-year, versus -92. 8% for Prothena Corporation plc (PRTA). Analysts rate Enanta Pharmaceuticals, Inc. (ENTA) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Amicus Therapeutics, Inc.

(FOLD) delivered a total return of +48. 6%, compared to -68. 9% for Enanta Pharmaceuticals, Inc. (ENTA). Over 10 years, the gap is even starker: FOLD returned +119. 2% versus PRTA's -73. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.

(FOLD) is the lower-risk stock at 0. 63β versus Enanta Pharmaceuticals, Inc. 's 1. 44β — meaning ENTA is approximately 129% more volatile than FOLD relative to the S&P 500. On balance sheet safety, Prothena Corporation plc (PRTA) carries a lower debt/equity ratio of 5% versus 3% for Enanta Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Agios Pharmaceuticals, Inc.

(AGIO) is pulling ahead at 48. 0% versus -92. 8% for Prothena Corporation plc (PRTA). On earnings-per-share growth, the picture is similar: Amicus Therapeutics, Inc. grew EPS 51. 2% year-over-year, compared to -161. 2% for Agios Pharmaceuticals, Inc.. Over a 3-year CAGR, AGIO leads at 56. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amicus Therapeutics, Inc.

(FOLD) is the more profitable company, earning -4. 3% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps -4. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FOLD leads at 5. 4% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — ENTA leads at 93. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Amicus Therapeutics, Inc.

(FOLD) trades at 40. 6x forward P/E versus 42. 7x for Prothena Corporation plc — 2. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ENTA: 219. 4% to $48. 20.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Amicus Therapeutics, Inc.

(FOLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 63), +119. 2% 10Y return). Both have compounded well over 10 years (FOLD: +119. 2%, ENTA: -40. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ENTA is a small-cap quality compounder stock; AGIO is a small-cap high-growth stock; FOLD is a small-cap high-growth stock; PRTA is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.